Tirzepatide Outperforms SGLT2 Inhibitors for Fatty Liver Disease Outcomes in Large Real-World Study | Research

The takeaway

In a propensity-matched study of 46,212 adults with MASLD, tirzepatide reduced the combined risk of death, cardiovascular events, and liver outcomes by 28% compared to SGLT2 inhibitors, with 45% lower all-cause mortality.

45% lower all-cause mortality vs SGLT2 inhibitors
Tirzepatide outperformed SGLT2 inhibitors across all outcomes in 46,212 propensity-matched MASLD patients — mortality, cardiovascular events, and liver outcomes

What the researchers found

After 1:1 propensity score matching of 23,106 patients per group from the TriNetX global network:

Tirzepatide vs SGLT2 inhibitors in MASLD:

- Primary composite (mortality + MACE + MALO): HR 0.72 (95% CI: 0.63-0.83) — 28% reduction

- All-cause mortality: HR 0.55 (95% CI: 0.43-0.71) — 45% reduction

- Major adverse cardiovascular events: HR 0.68 (95% CI: 0.58-0.80) — 32% reduction

- Major adverse liver outcomes: HR 0.66 (95% CI: 0.54-0.80) — 34% reduction

All associations were consistent across subgroups stratified by age, sex, BMI, and comorbidities, demonstrating robust benefit.

Why it matters

MASLD affects roughly 30% of the global population and is the fastest-growing cause of liver transplantation. No drug was specifically approved for MASLD until very recently, and clinicians must choose between several options. This is the first large head-to-head comparison showing tirzepatide is superior to SGLT2 inhibitors — one of the other leading treatment candidates — for hard clinical outcomes including death and liver failure progression. The magnitude of benefit (45% mortality reduction) is striking.

How the study worked

Retrospective multi-institutional cohort study using the TriNetX global research network. Adults ≥18 with MASLD newly initiated on tirzepatide or SGLT2 inhibitors between January 2022 and June 2025 were included. 1:1 propensity score matching balanced baseline characteristics. Cox proportional hazards models estimated hazard ratios for the composite primary outcome and individual components. Subgroup analyses assessed consistency across demographics and comorbidities.

What this study cannot tell us

Observational retrospective design — cannot establish causation despite propensity matching. The TriNetX database may have coding inaccuracies and ascertainment bias. Tirzepatide was approved more recently than SGLT2 inhibitors, so follow-up duration may differ. Indication bias is possible — sicker patients might be more likely to receive one drug over the other. The 45% mortality reduction is very large for an observational study and should be interpreted cautiously. Randomized controlled trials are needed for definitive comparison.

How to read the evidence

This is a large, well-designed observational study using propensity score matching from a global research network. The sample size (46,212 matched patients) and consistency across subgroups are strengths. However, as a retrospective non-randomized comparison, residual confounding cannot be excluded, and the large effect sizes warrant confirmation in randomized trials.

When this study was published

Published in 2026, this is a very current study reflecting real-world prescribing patterns with tirzepatide and SGLT2 inhibitors for MASLD, a rapidly evolving therapeutic area.

The bigger picture

This study positions tirzepatide — a dual GLP-1/GIP receptor agonist peptide — as potentially the most effective pharmacological treatment for MASLD. The dual receptor mechanism may provide advantages over single-target approaches by enhancing both metabolic improvement and direct liver protection. As MASLD overtakes hepatitis as the leading cause of chronic liver disease globally, identifying the optimal treatment is an urgent priority. This data, while observational, provides the strongest comparative evidence to date.

Questions still open

Will randomized head-to-head trials confirm tirzepatide's superiority over SGLT2 inhibitors for MASLD?
Does the dual GLP-1/GIP mechanism of tirzepatide provide liver-specific benefits beyond GLP-1 agonism alone?
Would combining tirzepatide with an SGLT2 inhibitor provide additional benefit over either drug alone?

Common questions

What is MASLD and why is it a growing health concern?

MASLD (metabolic dysfunction-associated steatotic liver disease), formerly called NAFLD, is a condition where excess fat builds up in the liver due to metabolic problems like obesity, diabetes, and insulin resistance. It affects about 30% of people globally and can progress to inflammation (steatohepatitis), scarring (cirrhosis), liver failure, and liver cancer. It's now the fastest-growing reason for liver transplants.

Why might tirzepatide work better than SGLT2 inhibitors for fatty liver?

Tirzepatide activates both GLP-1 and GIP receptors, producing greater weight loss and metabolic improvement than most other treatments. It also appears to have direct effects on liver fat metabolism. SGLT2 inhibitors work primarily by causing sugar excretion through the kidneys. While both reduce liver fat, tirzepatide's dual-receptor mechanism and greater weight loss may provide more comprehensive metabolic correction that better addresses the root causes of MASLD.

Read the original research

Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.

Hepatology international

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Jheng-Yan; Lin, Yu-Min; Hsu, Wan-Hsuan; Liu, Ting-Hui; Tsai, Ya-Wen; Huang, Po-Yu; Chuang, Min-Hsiang; Yu, Tsung; Lai, Chih-Cheng. (2026). Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.. Hepatology international. https://doi.org/10.1007/s12072-025-11021-z